Complementing this clinical evidence, NRF2 therapeutic potential for PD treatment is further supported by numerous in vitro and in vivo studies in which NRF2-ARE pathway activation demonstrates protective role in α-synucleinopathy PD models. Here, NFE2L2 is linked to synucleinopathy.